Thu, March 22, 2018
Wed, March 21, 2018
Tue, March 20, 2018
Mon, March 19, 2018
Fri, March 16, 2018
Thu, March 15, 2018
Wed, March 14, 2018
Tue, March 13, 2018
Mon, March 12, 2018
Fri, March 9, 2018
Thu, March 8, 2018
Wed, March 7, 2018
Tue, March 6, 2018
Mon, March 5, 2018
Fri, March 2, 2018
Thu, March 1, 2018

Debjit Chattopadhyay Maintained (SRPT) at Strong Buy with Increased Target to $92 on, Mar 12th, 2018


//stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-92-on-mar-12th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Debjit Chattopadhyay of HC Wainwright & Co., Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $75 to $92 on, Mar 12th, 2018.

Debjit has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Debjit's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Debjit


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $64 on, Tuesday, March 6th, 2018
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $75 on, Wednesday, February 21st, 2018
  • Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018

Publication Contributing Sources